• SSY Group received production and registration approvals from China's National Medical Products Administration for three drugs, all passing consistency evaluations.
• Products include tropicamide phenylephrine eye drops (0.4ml), tofacitinib citrate sustained-release tablets (11mg) and sacubitril valsartan sodium tablets (200mg).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261105-12401217), on November 05, 2026, and is solely responsible for the information contained therein.